Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

doi:10.1182/blood.2019002697

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

Blood - 30 Jan 2020

Döhner Konstanze, Thiede Christian, Jahn Nikolaus, Panina Ekaterina, Gambietz Agnes, Larson Richard A, Prior Thomas W, Marcucci Guido, Jones Dan, Krauter Jürgen, Heuser Michael, Voso Maria Teresa, Ottone Tiziana, Nomdedeu Josep F, Mandrekar Sumithra J, Klisovic Rebecca B, Wei Andrew H, Sierra Jorge, Sanz Miguel A, Brandwein Joseph M, de Witte Theo, Jansen Joop H, Niederwieser Dietger, Appelbaum Frederick R, Medeiros Bruno C, Tallman Martin S, Schlenk Richard F, Ganser Arnold, Serve Hubert, Ehninger Gerhard, Amadori Sergio, Gathmann Insa, Benner Axel, Pallaud Celine, Stone Richard M, Döhner Hartmut, Bloomfield Clara D

Abstract excerpt

Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (≥0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Duplication

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Multivariate Analysis

Share to Nucleophosmin

Share to Proportional Hazards Models

Share to Tandem Repeat Sequences

Source

Open in PubMed Open full text

Identifiers

PMID: 31826241
DOI: 10.1182/blood.2019002697
PMCID: PMC6993016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.PMID 31826241Read ↗

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsSemantic proximity Read ↗

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Semantic proximity Read ↗

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.Semantic proximity Read ↗

Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center ExperienceSemantic proximity Read ↗

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Acute Myeloid Leukaemia with Normal Cytogenetics and NPM1-Mutation: Impact of Mutation Topography on OutcomesSemantic proximity Read ↗

Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).Semantic proximity Read ↗

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.